Long-term safety of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria
Long-term safety of sustained eculizumab treatment in patients with paroxysmal nocturnal hemoglobinuria
[version 1; not peer reviewed]Drs Muus and Urbano-Ispizua have sat on an advisory board for Alexion Pharmaceuticals. Dr Roth has received honoraria and research funding from Alexion Pharmaceuticals. Dr Elebute has received honoraria from and sat on an advisory board for Alexion Pharmaceuticals. Dr Risitano has received research funding from and sat on an advisory board for Alexion Pharmaceuticals. Dr Maciejewski has received research funding from the NIH and the Aplastic Anemia and MDS International Foundation. Dr de Castro has served on a speakers' bureau for Alexion Pharmaceuticals. Drs Szer, Schrezenmeier, Socie, and Brodsky have nothing to disclose.
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
All commenters must hold a formal affiliation as per our Policies. The information that you give us will be displayed next to your comment.
User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.
Use of this website is subject to the F1000 Research Limited (F1000) General Terms and Conditions.
Submission of user comments to this website is subject to additional Terms and Conditions. By clicking "I accept the User Comment Terms and Conditions" before you submit your first comment, you agree to be bound by these conditions every time you submit a comment.
Terms relating to user comments